Meeting
2015 ASCO Annual Meeting
Biomarker analysis in recurrent and/or metastatic head and neck squamous cell carcinoma (R/M HNSCC) patients (pts) treated with second-line afatinib versus methotrexate (MTX): LUX-Head & Neck 1 (LUX-H&N1).
Authors
Ezra E. W. Cohen
UC San Diego Moores Cancer Center, La Jolla, CA
Ezra E. W. Cohen , Lisa F. Licitra , Jérôme Fayette , Thomas Christoph Gauler , Paul M. Clement , Juan José Grau , Jose Maria Del Campo , Audrey Mailliez , Robert I. Haddad , Jan B. Vermorken , Makoto Tahara , Joel Guigay , Lionnel Geoffrois , Marco C. Merlano , Nicholas F. Dupuis , Barbara Burtness , Neil Gibson , Flavio Solca , Eva Ehrnrooth , Jean-Pascal H. Machiels
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Head and Neck Cancer
Track
Head and Neck Cancer
Sub Track
Head and Neck Cancer
Clinical Trial Registration Number
NCT01345682
Citation
J Clin Oncol 33, 2015 (suppl; abstr 6023)
DOI
10.1200/jco.2015.33.15_suppl.6023
Abstract #
6023
Poster Bd #
346
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Afatinib in patients with recurrent/metastatic (RM) squamous cell carcinoma of the head and neck (SCCHN) harboring alterations in the HER pathway: Results of the B1 cohort of the EORTC-HNCG-1559 trial (UPSTREAM).
First Author: Rachel Galot
Poster
2012 ASCO Annual Meeting
LUX-H&N 1: A phase III, randomized trial of afatinib versus methotrexate (MTX) in patients (pts) with recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) who progressed after platinum-based therapy.
First Author: Jean-Pascal H. Machiels
Poster
2021 ASCO Annual Meeting
Afatinib and pembrolizumab for recurrent or metastatic head and neck squamous cell carcinoma (ALPHA Study): A phase II study with biomarker analysis.
First Author: Hsiang-fong Kao